{"id":"placebo-of-mci-186","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this formulation is pharmacologically inert and serves as a control comparator in clinical trials. It is used to establish the efficacy and safety profile of the active drug MCI-186 (edaravone) by comparison against a non-therapeutic baseline. The placebo arm allows for assessment of disease progression and spontaneous adverse events independent of active drug effects.","oneSentence":"This is a placebo control arm and contains no active pharmaceutical ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:18.443Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 trials for amyotrophic lateral sclerosis (ALS)"}]},"trialDetails":[{"nctId":"NCT04029090","phase":"PHASE1","title":"A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-09-18","conditions":"Healthy Adult Subjects","enrollment":27},{"nctId":"NCT07467746","phase":"PHASE2","title":"Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-04","conditions":"Amyotrophic Lateral Sclerosis","enrollment":84},{"nctId":"NCT00821821","phase":"PHASE2","title":"Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-02","conditions":"Acute Ischemic Stroke (AIS)","enrollment":36},{"nctId":"NCT03346538","phase":"PHASE2","title":"Dose Finding Study of MCI-186 in Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-11-17","conditions":"Acute Ischemic Stroke","enrollment":17},{"nctId":"NCT04481750","phase":"PHASE1","title":"Study of Oral Edaravone in Healthy Adult Males","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-03-20","conditions":"Healthy Adult Subjects","enrollment":74},{"nctId":"NCT01492686","phase":"PHASE3","title":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":137},{"nctId":"NCT00424463","phase":"PHASE3","title":"Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2007-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":181},{"nctId":"NCT00330681","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-05","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":206},{"nctId":"NCT00415519","phase":"PHASE3","title":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":25},{"nctId":"NCT05151471","phase":"PHASE3","title":"Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2022-01-11","conditions":"ALS","enrollment":202},{"nctId":"NCT04569084","phase":"PHASE3","title":"Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS","status":"TERMINATED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-11-13","conditions":"ALS","enrollment":384},{"nctId":"NCT06674460","phase":"PHASE3","title":"Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-08-01","conditions":"Cerebral Small Vessel Disease, Ischemic Stroke","enrollment":600},{"nctId":"NCT06315231","phase":"PHASE2","title":"Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients","status":"RECRUITING","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2024-04-08","conditions":"Post-stroke Cognitive Impairment","enrollment":226},{"nctId":"NCT07138014","phase":"PHASE2","title":"FHND1002 for ALS Treatment: Phase 2","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":180},{"nctId":"NCT07119021","phase":"PHASE4","title":"Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)","status":"RECRUITING","sponsor":"Ruijun Ji","startDate":"2024-08-01","conditions":"Ischemic Stroke","enrollment":300},{"nctId":"NCT05323812","phase":"PHASE2","title":"ASURE: Alzheimer Study Using oRal Edaravone","status":"COMPLETED","sponsor":"Treeway B.V.","startDate":"2023-03-01","conditions":"Alzheimer Disease","enrollment":61},{"nctId":"NCT05178810","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2021-10-18","conditions":"Amyotrophic Lateral Sclerosis","enrollment":313},{"nctId":"NCT04370431","phase":"PHASE1","title":"A Study of TTYP01 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2020-04-24","conditions":"Healthy Adult Subjects","enrollment":72},{"nctId":"NCT06645522","phase":"PHASE4","title":"Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Yi Yang","startDate":"2024-10-30","conditions":"Acute Ischemic Stroke","enrollment":1200},{"nctId":"NCT04984577","phase":"PHASE2","title":"Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke","status":"SUSPENDED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2021-11-15","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT06176781","phase":"PHASE3","title":"The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-12-28","conditions":"Subjects With Acute Ischemic Stroke","enrollment":880},{"nctId":"NCT05249920","phase":"PHASE3","title":"Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-03-18","conditions":"Acute Ischemic Stroke, Mechanical Thrombectomy, Edaravone Dexborneol","enrollment":1362},{"nctId":"NCT04950920","phase":"PHASE3","title":"Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2021-06-28","conditions":"Stroke","enrollment":914},{"nctId":"NCT05953103","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-07-03","conditions":"Subjects With Cerebral Hemorrhage","enrollment":380},{"nctId":"NCT05885919","phase":"PHASE3","title":"Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-07-01","conditions":"Ischemic Stroke, Acute, Treatment Outcome","enrollment":212},{"nctId":"NCT04667637","phase":"PHASE2","title":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol","status":"COMPLETED","sponsor":"Hui-Sheng Chen","startDate":"2021-02-23","conditions":"Stroke, Endovascular Thrombectomy","enrollment":200},{"nctId":"NCT05035953","phase":"PHASE2","title":"Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-09-13","conditions":"Stroke, Ischemic","enrollment":200},{"nctId":"NCT04219865","phase":"PHASE1","title":"Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection","status":"COMPLETED","sponsor":"Nanjing Yoko Biomedical Co., Ltd.","startDate":"2019-06-05","conditions":"Pharmacokinetics","enrollment":40},{"nctId":"NCT04714177","phase":"PHASE2","title":"Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-03-01","conditions":"Intracerebral Hemorrhage","enrollment":390},{"nctId":"NCT00265239","phase":"PHASE4","title":"Pilot Study of Edaravone to Treat Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2001-04","conditions":"Myocardial Infarction, Reperfusion Injury","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of MCI-186","genericName":"Placebo of MCI-186","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control arm and contains no active pharmaceutical ingredient. Used for Control arm in phase 3 trials for amyotrophic lateral sclerosis (ALS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}